Reply to C. Nabhan et al

Qiushi Chen; Nitin Jain; Christopher R. Flowers; Jagpreet Chhatwal

doi:10.1200/JCO.2017.72.2769

Reply to C. Nabhan et al

Qiushi Chen, Nitin Jain, Christopher R. Flowers, Jagpreet Chhatwal

Leukemia

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1864-1865
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	35
Issue number	16
DOIs	https://doi.org/10.1200/JCO.2017.72.2769
State	Published - Jun 1 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2017.72.2769

Cite this

@article{bd0ea4088b3340dbb0f634dea1661d08,

title = "Reply to C. Nabhan et al",

author = "Qiushi Chen and Nitin Jain and Flowers, {Christopher R.} and Jagpreet Chhatwal",

note = "Funding Information: Pharmacyclics (Inst), AbbVie (Inst), Genentech (Inst), Pharmacyclics (Inst), Infinity Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Pfizer (Inst), ADC Therapeutics (Inst), Seattle Genetics (Inst), Incyte (Inst), Servier (Inst), Celgene (Inst) Gilead Sciences (Inst) Acerta Pharma (Inst), Infinity Pharmaceuticals (Inst), Onyx (Inst), Janssen Oncology (Inst), Gilead Sciences (Inst), Celgene (Inst), TG Therapeutics (Inst), Genentech (Inst), Pharmacyclics (Inst), AbbVie (Inst)",

year = "2017",

month = jun,

day = "1",

doi = "10.1200/JCO.2017.72.2769",

language = "English (US)",

volume = "35",

pages = "1864--1865",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

TY - JOUR

T1 - Reply to C. Nabhan et al

AU - Chen, Qiushi

AU - Jain, Nitin

AU - Flowers, Christopher R.

AU - Chhatwal, Jagpreet

N1 - Funding Information: Pharmacyclics (Inst), AbbVie (Inst), Genentech (Inst), Pharmacyclics (Inst), Infinity Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Pfizer (Inst), ADC Therapeutics (Inst), Seattle Genetics (Inst), Incyte (Inst), Servier (Inst), Celgene (Inst) Gilead Sciences (Inst) Acerta Pharma (Inst), Infinity Pharmaceuticals (Inst), Onyx (Inst), Janssen Oncology (Inst), Gilead Sciences (Inst), Celgene (Inst), TG Therapeutics (Inst), Genentech (Inst), Pharmacyclics (Inst), AbbVie (Inst)

PY - 2017/6/1

Y1 - 2017/6/1

UR - http://www.scopus.com/inward/record.url?scp=85021855777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021855777&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.72.2769

DO - 10.1200/JCO.2017.72.2769

M3 - Letter

C2 - 28549223

AN - SCOPUS:85021855777

SN - 0732-183X

VL - 35

SP - 1864

EP - 1865

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Reply to C. Nabhan et al

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this